Neil F. McFarlane

This profile gathers the share dealings of Neil F. McFarlane across 4 companies, led by Travere Therapeutics, Inc., Zevra Therapeutics, Inc. and Adamas Pharmaceuticals Inc. The record holds 32 filings, for trades running from 15 August 2016 to 12 October 2026.

Sales make up the whole of the open-market record (13 sales, €2.4M). The rest of the record consists of 13 share grants and 5 option exercises. In 2026 alone, the filings show no purchases and 3 sales.

Most recently, on 13 October 2026, the filings show an option exercise in Zevra Therapeutics, Inc. Typically, a trade is published a median of 1 day after it takes place. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.